# Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

> **NCT01897012** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 26 (actual)

## Conditions studied

- MYC Positive
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Burkitt Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Recurrent Hodgkin Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Burkitt Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma
- Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Refractory Hodgkin Lymphoma
- Refractory Mantle Cell Lymphoma
- Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Alisertib
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Romidepsin

## Key facts

- **NCT ID:** NCT01897012
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-17
- **Primary completion:** 2018-10-31
- **Final completion:** 2018-11-30
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2019-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01897012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01897012, "Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01897012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*